Skip to main content

Table 2 HNSCC, postoperative radio- radiochemotherapy by PSMD1-score

From: Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

PSMD1-score

1 (n=26)

2 (n=27)

3 (n=39)

Age (years) mean

63.4

60.8

60.2

Q1/Q2/Q3

58.5/64/70.2

52/60/70

51/61/68

Male (%)

88.4

81.4

73.6

Weight (kg) mean

64.9

68.8

67.7

Q1/Q2/Q3

57.8/64.5/73

56.8/68.8/77.5

57.8/68.7/77.6

Smoker (n)

7/26

17/26

17/39

Karnofski >= 70% (n)

19/19

19/20

30/30

Hemoglobin level (mg/dL) mean

12.7

12.7

12.0

Q1/Q2/Q3

12.0/12.6/13.6

11.1/13.1/14

11.2/11.9/12.9

Unknown primary

 

1 (3.7)

 

Oral cavity n (%)

7 (26.9)

8 (29.6)

9 (23.0)

Oropharynx n (%)

9 (34.6)

10 (37.0)

16 ( 41.0)

Hypopharynx n (%)

5 (19.2)

2 (7.4)

8 (20.5)

Larynx n (%)

5 (19.2)

6 (22.2)

6 (15.3)

cT0 n (%)

 

1 (3.8)

3 (7.6)

cT1 n (%)

7 (26.9)

2 (7.6)

7 (17.9)

cT2 n (%)

8 (30.7)

8 (30.7)

11 (28.2)

cT3 n (%)

6 (23.0)

6 (23.0)

11 (28.2)

cT4 n (%)

5 (19.2)

9 (34.6)

7 (17.9)

cN0 n (%)

2 (7.6)

6 (22.2)

5 (12.8)

cN1 n (%)

5 (19.2)

4 (14.8)

14 (35.8)

cN2 n (%)

18 (69.2)

14 (51.8)

19 (48.6)

cN3 n (%)

1 (3.8)

3 (11.1)

1 (2.5)

G1 n (%)

 

1 (3.7)

1 (2.5)

G2 n (%)

12 (46.1)

15 (55.5)

21 (53.8)

G3 n (%)

14 (53.8)

11 (40.7)

17 (43.5)

EpoR (C20+) (%)

17 (65.3)

24 (88.8)

26 (66.6)

RT (Gy) mean

62.9

63.9

62.2

Q1/Q2/Q3

60/64/64

63/64/66

60/63/64

RT (days)

46.9

46.3

45.7

Q1/Q2/Q3

43/45/48

44/45/50

43.7/44.5/47.5

Treated in study A1/C3/D4 (n)

3/22/1

6/18/3

4/31/4

Local control (months) median

nr

nr

nr

Survival (months) median; 95% CI

48.2; 12.4-92.6

29.3; 13–74.1

42.8; 20.7-66.2